Quantcast

Latest Amyloid precursor protein secretase Stories

2010-09-01 11:55:00

NEW YORK, Sept. 1 /PRNewswire-USNewswire/ -- Researchers at the Fisher Center for Alzheimer's Disease Research laboratory today published "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease" in Nature online. Drs. Gen He (lead author) and Paul Greengard have discovered a protein that stimulates the production of beta-amyloid, and therefore represents a major new advance in Alzheimer's disease research. The protein, called gamma-secretase activating protein...

2010-07-14 12:00:00

HONOLULU, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease. EVP-0015962...

2010-06-04 14:13:39

Reducing a protein called beta-amyloid in young mice with a condition resembling Down syndrome improves their ability to learn, researchers at UT Southwestern Medical Center have found. "This preliminary study in the animal model raises the intriguing possibility that drugs that lower beta-amyloid levels might offer some benefit to children with Down syndrome," said Dr. Craig Powell, assistant professor of neurology at UT Southwestern and co-lead author of the study, which is available in...

2009-12-08 08:00:00

WATERTOWN, Mass., Dec. 8 /PRNewswire/ -- EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease. The reduction of these aggregates further supports the disease...

2009-07-14 11:49:00

VIENNA, July 14 /PRNewswire/ -- EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) the reversal of behavioral deficits observed in an Alzheimer's disease transgenic animal model after chronic oral dosing of a proprietary gamma-secretase modulator (GSM). The data was disclosed as part of the preclinical characterization of the development candidate EVP-0962. EVP-0962 is a proprietary small molecule that belongs...

2009-07-13 07:05:00

They say the findings cement relationship between the two brain disordersThe destructive cellular pathways activated in Alzheimer's disease are also triggered following traumatic brain injury, say researchers from Georgetown University Medical Center (GUMC). They say this finding suggests that novel therapy might successfully target both conditions.In an oral presentation at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease, the scientists will show that...

2009-04-22 10:08:17

Taking a new approach to the treatment and prevention of Alzheimer's disease, a research team led by investigators at the Mayo Clinic campus in Florida has shown that druglike compounds can speed up destruction of the amyloid beta (A-beta) proteins that form plaque in the brains of patients with the disorder.Researchers say their study, published in the April 22 online issue of PLoS ONE, demonstrates that this strategy is a viable and exciting alternative to the approach most drug designers...

2009-02-26 00:30:00

PARIS, February 26 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) is pleased to announce that clinical testing of EHT 0202, its lead compound in Alzheimer's disease, is progressing well. Patient enrolment for the Phase IIa trial assessing EHT 0202 in patients with Alzheimer's disease is completed. "The successful completion of patient enrolment for the Phase IIa represents an important milestone in the development of EHT 0202, and provides a clear timeline for the...

2008-11-11 12:00:26

TorreyPines Therapeutics, a biopharmaceutical company, has agreed to sell its Alzheimer's disease genetics research program to Eisai for an upfront cash payment. TorreyPines and Eisai have collaborated on the genetics program since 2002, with the most recent agreement between the parties concluding on September 30, 2008. The Alzheimer's disease genetics research program focused on the discovery of Alzheimer's disease targets using whole-genome family-based association screening. The...

2008-10-21 15:00:28

SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease. Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D., was created based on the groundbreaking research that their team has been conducting in Florida...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related